Targeting KRAS in Lung Cancer: Current Status and Future Directions
A special issue of Current Oncology (ISSN 1718-7729). This special issue belongs to the section "Thoracic Oncology".
Deadline for manuscript submissions: 30 June 2026 | Viewed by 65
Special Issue Editor
Special Issue Information
Dear Colleagues,
The Special Issue aims to provide a comprehensive overview of the latest advances and challenges in targeting KRAS-driven lung cancers. KRAS mutations are among the most common oncogenic drivers in non-small cell lung cancer (NSCLC), yet they have historically posed significant therapeutic challenges. With the recent approval of KRAS G12C inhibitors and ongoing development of novel therapeutic strategies, this issue seeks to explore the evolving landscape of KRAS-targeted therapies in both early and advanced disease settings. Topics of interest include molecular diagnostics, mechanism-based therapeutics, resistance mechanisms, combination therapies, and real-world clinical outcomes. We also welcome contributions on biomarker development, translational research, and innovative trial designs that may shape future directions in KRAS-mutant lung cancer management. This issue emphasizes stage-dependent treatment strategies, molecular characterization, and the integration of systemic therapies to improve patient survival and quality of life.
Dr. Sally Lau
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Current Oncology is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2200 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- KRAS mutations
- non-small cell lung cancer
- targeted therapy
- KRAS G12C inhibitors
- translational research
- combination therapy
- clinical outcomes
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.
Further information on MDPI's Special Issue policies can be found here.
